Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Entera Bio ( (ENTX) ) has issued an announcement.
Entera Bio announced its second quarter 2025 financial results and business updates, highlighting significant regulatory advancements for its EB613 osteoporosis treatment, including FDA agreement on Phase 3 design and a waiver of additional safety studies. The company also reported strong progress in its collaboration with OPKO Health, showcasing promising preclinical data in its obesity program and maintaining a robust financial position with $18.9 million in cash, supporting operations through mid-Q3 2026.
The most recent analyst rating on (ENTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.
Spark’s Take on ENTX Stock
According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.
Entera Bio’s overall stock score reflects a balance between financial challenges and strategic advancements. The company’s financial instability and cash flow issues weigh significantly on the score. However, positive corporate events and strong technical momentum provide some optimism, though valuation remains a concern due to negative earnings.
To see Spark’s full report on ENTX stock, click here.
More about Entera Bio
Entera Bio is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs, leveraging a proprietary technology platform called N-Tab™. The company is advancing a pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2, with its most advanced product candidate being EB613, an oral treatment for osteoporosis.
Average Trading Volume: 118,020
Technical Sentiment Signal: Sell
Current Market Cap: $90M
Learn more about ENTX stock on TipRanks’ Stock Analysis page.